Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.67 |
| ▸ | BRAF | P15056 | 6/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.53 |
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18069413 | 0.82 | TGFBR1 (0.53) | TGFBR1 | |
| SCHEMBL29833474 | 0.81 | TGFBR1 (1.00) | TGFBR1BRAFMAPK13KDRMAPK12 | |
| SCHEMBL18005294 | 0.81 | TGFBR1 (1.00) | TGFBR1BRAFMAPK13KDRMAPK12 | |
| SCHEMBL29833468 | 0.78 | TGFBR1 (1.00) | TGFBR1BRAFMAPK13KDRMAPK12 | |
| SCHEMBL18005137 | 0.78 | TGFBR1 (1.00) | TGFBR1BRAFMAPK13KDRMAPK12 | |
| SCHEMBL2950612 | 0.78 | PIK3CA (0.56) | TGFBR1BRAFMAPK13KDRMAPK12 | |
| SCHEMBL15638469 | 0.77 | PTK2 (0.56) | MTORPIK3CDPIK3CGPIK3C3 | |
| SCHEMBL15639561 | 0.77 | TGFBR1 (0.47) | TGFBR1 | |
| SCHEMBL22380055 | 0.77 | LRRK2 (0.77) | TGFBR1BRAFMAPK13KDRMAPK12 | |
| SCHEMBL29537871 | 0.77 | LRRK2 (0.77) | TGFBR1BRAFMAPK13KDRMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3259264-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3259264-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264553-A1 | GDF-8 Inhibitors | CXCL8, MSTN, LGALS8 | TGFBR1 249/4885BRAF 2283/4885MAPK13 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.